secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001558370-24-014749
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Therapeutics Q3 net loss $2.3M; cash runway depends on $3M Feb 2025 tranche
--------------------------------------------------------------------------------

- Net loss $2.3M ($2.05/share) vs $1.2M ($1.62) in Q3 2023; R&D and G&A expenses rose.
- Cash $2.0M at Sep 30; $16.5M loan from CKLS affiliate received Oct 7; $3M tranche needed Feb 2025 to fund through 2025.
- Top-line results from IMC-2 Long-COVID Phase 2a study expected mid-November 2024.
- Halneuron Phase 2b CINP interim data expected 2H 2025; FDA fast-track designation granted.
- Company formed via combination of Virios and Pharmagesic; pipeline includes IMC-1, IMC-2, and Halneuron.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024014749/0001558370-24-014749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024014749/viri-20241107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer